| 000 | 01863 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515045106.0 | ||
| 264 | 0 | _c20070116 | |
| 008 | 200701s 0 0 eng d | ||
| 022 | _a0007-0920 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6603440 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPittman, K B | |
| 245 | 0 | 0 |
_aGemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cNov 2006 |
||
| 300 |
_a1309-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aAustralia |
| 650 | 0 | 4 |
_aCarboplatin _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Large Cell _xdrug therapy |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms, Unknown Primary _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aOlver, I N | |
| 700 | 1 | _aKoczwara, B | |
| 700 | 1 | _aKotasek, D | |
| 700 | 1 | _aPatterson, W K | |
| 700 | 1 | _aKeefe, D M | |
| 700 | 1 | _aKarapetis, C S | |
| 700 | 1 | _aParnis, F X | |
| 700 | 1 | _aMoldovan, S | |
| 700 | 1 | _aYeend, S J | |
| 700 | 1 | _aPrice, T J | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 95 _gno. 10 _gp. 1309-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6603440 _zAvailable from publisher's website |
| 999 |
_c16662052 _d16662052 |
||